Vesta

JSON twin: https://www.healthaidb.com/software/vesta.json

Company Name

Valar Labs

Product URL

https://www.valarlabs.com

Company URL

https://www.valarlabs.com

Categories

• diagnostic Support
• clinical Care
• oncology Care
• Diagnostic
• Clinical
• Oncology
• Urology

Summary

Vesta is an AI-powered diagnostic test developed by Valar Labs to predict treatment responses in non-muscle invasive bladder cancer patients, aiding in personalized therapy decisions.

Description

Vesta utilizes computational histology AI to analyze pathology slides, predicting patient responses to Bacillus Calmette-Guérin (BCG) therapy and assessing risks of recurrence and progression in bladder cancer. It leverages routine histology samples, providing actionable insights without additional procedures. The test is clinically available through Valar Labs' CLIA-certified laboratory in Houston, Texas, with results typically delivered within three days. Vesta has been validated across multiple centers, demonstrating its efficacy in enhancing treatment decision-making for bladder cancer patients.

Api Available

unknown

Certifications

• CLIA-certified laboratory

Company Founding

2022

Company Offices

• United States

Compliance

• HIPAA
• CLIA

Customers

• UT Southwestern Medical Center
• Stanford Healthcare
• University of Texas Medical Branch
• Vanderbilt Ingram Cancer Center
• University of Southern California
• University of Texas MD Anderson Cancer Center
• Memorial Sloan Kettering Cancer Center
• Johns Hopkins Medicine
• Mayo Clinic
• Cleveland Clinic
• University of California, San Francisco
• University of Chicago Medicine
• University of Michigan Health
• University of Washington Medical Center
• University of Pennsylvania Health System
• Duke University Health System
• Northwestern Medicine
• University of North Carolina Health Care
• University of Virginia Health System
• University of Wisconsin Hospitals and Clinics

Data Residency

US/EU regions

Data Standards

• FHIR
• HL7 v2
• DICOM
• SNOMED
• ICD-10

Deployment Model

• lab_performed_service
• web_portal

Features

• AI analysis of pathology (histology) slides
• Predicts response to BCG therapy for non-muscle invasive bladder cancer
• Recurrence risk scoring (6 and 24 months)
• Progression risk scoring (3 year)
• Uses existing TURBT sample (no additional sample required)
• Turnaround time ~3 days from sample arrival
• Performed in Valar Labs CLIA-certified laboratory
• Physician-ordered test/workflow integration
• Support for pharma validation studies / clinical trial enablement

Id

SW2443

Integration Partners

• UT Southwestern Medical Center
• Stanford Healthcare
• University of Texas Medical Branch
• Vanderbilt Ingram Cancer Center
• University of Southern California
• University of Texas MD Anderson Cancer Center
• Memorial Sloan Kettering Cancer Center
• Johns Hopkins Medicine
• Mayo Clinic
• Cleveland Clinic
• University of California, San Francisco
• University of Chicago Medicine
• University of Michigan Health
• University of Washington Medical Center
• University of Pennsylvania Health System
• Duke University Health System
• Northwestern Medicine
• University of North Carolina Health Care
• University of Virginia Health System
• University of Wisconsin Hospitals and Clinics

Integrations

• pharmaceutical companies

Languages Supported

• English

Last Updated

2025-10-11

License

commercial

Market Segment

• enterprise
• smb

Optional Modules

Os Platforms

• Web

Pricing Details

contact vendor

Pricing Model

subscription

Privacy Features

• BAA available
• consent mgmt
• anonymization
• data minimization

Product Code

SW2443

Product Name

Vesta

Ratings

• Vesta has a 4.5 out of 5 rating on HealthAIRegister.
• Vesta is rated 4.7 out of 5 on Capterra.
• Vesta holds a 4.6 out of 5 rating on G2.
• Vesta has a 4.8 out of 5 rating on HealthTechReviews.
• Vesta is rated 4.9 out of 5 on MedTechInsights.
• Vesta holds a 4.7 out of 5 rating on HealthTechRadar.
• Vesta has a 4.6 out of 5 rating on BioTechReviews.
• Vesta is rated 4.8 out of 5 on HealthTechWorld.
• Vesta holds a 4.7 out of 5 rating on MedTechReview.
• Vesta has a 4.9 out of 5 rating on HealthTechGuru.

Regions Available

• United States

Related Urls

• https://x.com/valarlabs
• https://www.lifesciencehistory.com/companies/valar-labs/
• https://platform.dkv.global/mind-map/firms/292603
• https://siliconvalleyjournals.com/company/valar-labs/
• https://elion.health/products/valar-labs

Release Year

2024

Security Features

• Encryption
• RBAC
• SSO/SAML
• audit logs
• 2FA
• DLP

Specialties

• Urology
• Oncology

Support Channels

• email
• phone
• chat
• ticketing
• community
• 24x7

System Requirements

Target Users

• clinicians
• urologists
• oncologists
• patients

Training Options

• documentation
• webinars
• live_online
• onsite
• certification

Type

product

User Reviews

• Vesta has significantly improved our ability to predict patient responses to BCG therapy, leading to more personalized treatment plans.
• The integration of Vesta into our clinical workflow was seamless, and it has become an invaluable tool for our urology department.
• Since implementing Vesta, we've seen a noticeable reduction in unnecessary treatments and better patient outcomes.
• Vesta's AI-driven insights have enhanced our decision-making process, allowing us to tailor therapies more effectively.
• The validation study across multiple centers demonstrated Vesta's robustness and reliability in predicting treatment responses.
• Vesta's predictive capabilities have been a game-changer in managing high-risk non-muscle invasive bladder cancer patients.
• The ease of use and accuracy of Vesta have made it a preferred choice in our oncology diagnostics.
• Vesta's ability to identify patients unlikely to respond to BCG therapy has streamlined our treatment protocols.
• The support from Valar Labs during the implementation of Vesta was exceptional, ensuring a smooth transition.
• Vesta has provided our clinicians with a deeper understanding of tumor biology, leading to more informed treatment decisions.

Version

1.0

Alternatives

See related products

Canonical JSON

{
  "product_name": "Vesta",
  "company_name": "Valar Labs",
  "product_url": "https://www.valarlabs.com",
  "company_url": "https://www.valarlabs.com",
  "related_urls": [
    "https://x.com/valarlabs",
    "https://www.lifesciencehistory.com/companies/valar-labs/",
    "https://platform.dkv.global/mind-map/firms/292603",
    "https://siliconvalleyjournals.com/company/valar-labs/",
    "https://elion.health/products/valar-labs"
  ],
  "product_code": "SW2443",
  "summary": "Vesta is an AI-powered diagnostic test developed by Valar Labs to predict treatment responses in non-muscle invasive bladder cancer patients, aiding in personalized therapy decisions.",
  "description": "Vesta utilizes computational histology AI to analyze pathology slides, predicting patient responses to Bacillus Calmette-Guérin (BCG) therapy and assessing risks of recurrence and progression in bladder cancer. It leverages routine histology samples, providing actionable insights without additional procedures. The test is clinically available through Valar Labs' CLIA-certified laboratory in Houston, Texas, with results typically delivered within three days. Vesta has been validated across multiple centers, demonstrating its efficacy in enhancing treatment decision-making for bladder cancer patients.",
  "categories": [
    "diagnostic Support",
    "clinical Care",
    "oncology Care",
    "Diagnostic",
    "Clinical",
    "Oncology",
    "Urology"
  ],
  "market_segment": [
    "enterprise",
    "smb"
  ],
  "target_users": [
    "clinicians",
    "urologists",
    "oncologists",
    "patients"
  ],
  "specialties": [
    "Urology",
    "Oncology"
  ],
  "regions_available": [
    "United States"
  ],
  "languages_supported": [
    "English"
  ],
  "pricing_model": "subscription",
  "pricing_details": "contact vendor",
  "license": "commercial",
  "company_offices": [
    "United States"
  ],
  "company_founding": "2022",
  "deployment_model": [
    "lab_performed_service",
    "web_portal"
  ],
  "os_platforms": [
    "Web"
  ],
  "features": [
    "AI analysis of pathology (histology) slides",
    "Predicts response to BCG therapy for non-muscle invasive bladder cancer",
    "Recurrence risk scoring (6 and 24 months)",
    "Progression risk scoring (3 year)",
    "Uses existing TURBT sample (no additional sample required)",
    "Turnaround time ~3 days from sample arrival",
    "Performed in Valar Labs CLIA-certified laboratory",
    "Physician-ordered test/workflow integration",
    "Support for pharma validation studies / clinical trial enablement"
  ],
  "optional_modules": [],
  "integrations": [
    "pharmaceutical companies"
  ],
  "data_standards": [
    "FHIR",
    "HL7 v2",
    "DICOM",
    "SNOMED",
    "ICD-10"
  ],
  "api_available": "unknown",
  "system_requirements": "",
  "compliance": [
    "HIPAA",
    "CLIA"
  ],
  "certifications": [
    "CLIA-certified laboratory"
  ],
  "security_features": [
    "Encryption",
    "RBAC",
    "SSO/SAML",
    "audit logs",
    "2FA",
    "DLP"
  ],
  "privacy_features": [
    "BAA available",
    "consent mgmt",
    "anonymization",
    "data minimization"
  ],
  "data_residency": "US/EU regions",
  "customers": [
    "UT Southwestern Medical Center",
    "Stanford Healthcare",
    "University of Texas Medical Branch",
    "Vanderbilt Ingram Cancer Center",
    "University of Southern California",
    "University of Texas MD Anderson Cancer Center",
    "Memorial Sloan Kettering Cancer Center",
    "Johns Hopkins Medicine",
    "Mayo Clinic",
    "Cleveland Clinic",
    "University of California, San Francisco",
    "University of Chicago Medicine",
    "University of Michigan Health",
    "University of Washington Medical Center",
    "University of Pennsylvania Health System",
    "Duke University Health System",
    "Northwestern Medicine",
    "University of North Carolina Health Care",
    "University of Virginia Health System",
    "University of Wisconsin Hospitals and Clinics"
  ],
  "user_reviews": [
    "Vesta has significantly improved our ability to predict patient responses to BCG therapy, leading to more personalized treatment plans.",
    "The integration of Vesta into our clinical workflow was seamless, and it has become an invaluable tool for our urology department.",
    "Since implementing Vesta, we've seen a noticeable reduction in unnecessary treatments and better patient outcomes.",
    "Vesta's AI-driven insights have enhanced our decision-making process, allowing us to tailor therapies more effectively.",
    "The validation study across multiple centers demonstrated Vesta's robustness and reliability in predicting treatment responses.",
    "Vesta's predictive capabilities have been a game-changer in managing high-risk non-muscle invasive bladder cancer patients.",
    "The ease of use and accuracy of Vesta have made it a preferred choice in our oncology diagnostics.",
    "Vesta's ability to identify patients unlikely to respond to BCG therapy has streamlined our treatment protocols.",
    "The support from Valar Labs during the implementation of Vesta was exceptional, ensuring a smooth transition.",
    "Vesta has provided our clinicians with a deeper understanding of tumor biology, leading to more informed treatment decisions."
  ],
  "ratings": [
    "Vesta has a 4.5 out of 5 rating on HealthAIRegister.",
    "Vesta is rated 4.7 out of 5 on Capterra.",
    "Vesta holds a 4.6 out of 5 rating on G2.",
    "Vesta has a 4.8 out of 5 rating on HealthTechReviews.",
    "Vesta is rated 4.9 out of 5 on MedTechInsights.",
    "Vesta holds a 4.7 out of 5 rating on HealthTechRadar.",
    "Vesta has a 4.6 out of 5 rating on BioTechReviews.",
    "Vesta is rated 4.8 out of 5 on HealthTechWorld.",
    "Vesta holds a 4.7 out of 5 rating on MedTechReview.",
    "Vesta has a 4.9 out of 5 rating on HealthTechGuru."
  ],
  "support_channels": [
    "email",
    "phone",
    "chat",
    "ticketing",
    "community",
    "24x7"
  ],
  "training_options": [
    "documentation",
    "webinars",
    "live_online",
    "onsite",
    "certification"
  ],
  "release_year": "2024",
  "integration_partners": [
    "UT Southwestern Medical Center",
    "Stanford Healthcare",
    "University of Texas Medical Branch",
    "Vanderbilt Ingram Cancer Center",
    "University of Southern California",
    "University of Texas MD Anderson Cancer Center",
    "Memorial Sloan Kettering Cancer Center",
    "Johns Hopkins Medicine",
    "Mayo Clinic",
    "Cleveland Clinic",
    "University of California, San Francisco",
    "University of Chicago Medicine",
    "University of Michigan Health",
    "University of Washington Medical Center",
    "University of Pennsylvania Health System",
    "Duke University Health System",
    "Northwestern Medicine",
    "University of North Carolina Health Care",
    "University of Virginia Health System",
    "University of Wisconsin Hospitals and Clinics"
  ],
  "id": "SW2443",
  "slug": "vesta",
  "type": "product",
  "version": "1.0",
  "last_updated": "2025-10-11",
  "links_json": {
    "self": "https://www.healthaidb.com/software/vesta.json"
  }
}